Le Année d'introduction en bourse de Solarvest BioEnergy, Inc. est 2006
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Solarvest BioEnergy Inc. engages in the development of algal-based production systems to produce natural based green commercial products in Canada and internationally. The company provides human nutrition products, including omega-3; and pharmaceutical ingredients for human health comprising cannabinoids in algae and bone morphogenetic protein for the treatment of repairing bone fractures. It has a collaborative research and development agreement with FSD Pharma Inc. to develop algae-based pharmaceutical grade cannabinoids. The company was incorporated in 2005 and is based in Vancouver, Canada.